FIELD: medicine.
SUBSTANCE: invention refers to medicine and can be used for treating a human patient suffering acid lysosome lipase (ALL) deficiency. That is ensured by administering human recombinant ALL into the above human patient in an amount effective to normalise hepatic transaminase in serum or blood. The above human recombinant ALL is administered once approximately every 7 days to once approximately every 30 days, and the above dose is adequate to reducing the hepatic involvement in the above human patient.
EFFECT: invention provides treating the ALL deficiency, such as Wolman disease, cholesterol ester storage disease (CESD) both at the early, and late stages of the disease.
32 cl, 19 dwg, 12 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LYSOSOMAL STORAGE DISORDER ENZYME | 2011 |
|
RU2575074C2 |
| LYSOSOMAL DISEASE ACCUMULATION ENZYME | 2017 |
|
RU2741116C2 |
| USING LCAT FOR TREATING ANAEMIA AND RED BLOOD CELL DISORDERS | 2010 |
|
RU2576838C2 |
| COMPOSITIONS AND METHODS FOR IMPROVING SOMATOSTATIN IMMUNOGENICITY IN TREATING GROWTH HORMONE AND INSULIN-LIKE GROWTH FACTOR DEFICIENCY | 2009 |
|
RU2519051C2 |
| METHODS FOR DIAGNOSING AND TREATING RELATED TO TH2 INHIBITION | 2011 |
|
RU2578468C2 |
| INTRAVENTRICULAR DELIVERY OF ENZYMES IN LYSOSOMAL STORAGE DISEASES | 2014 |
|
RU2665381C2 |
| PRODUCTION OF ACTIVE HIGHLY PHOSPHORYLATED N-ACETYLGALACTOSAMINE-6-SULPHATASE AND USE THEREOF | 2011 |
|
RU2607376C2 |
| INTRAVENTRICULAR DELIVERY OF ENZYMES IN CASE OF LYSOSOMAL STORAGE DISEASES | 2007 |
|
RU2529830C2 |
| PHARMACEUTICAL COMPOSITION AND METHOD OF PREVENTION AND TREATMENT OF LYSOSOMAL ENZYME DEFICIENCY IN SUBJECT WITH TYPE II MUCOPOLYSACCHARIDOSIS | 2023 |
|
RU2814280C1 |
| METHODS OF TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | 2020 |
|
RU2824599C2 |
